Physicians' Academy for Cardiovascular Education

The latest evidence of SGLT2i in CKD

Listen to the podcast
10' education - May 16, 2023 - Will Herrington, MD – Oxford, UK

Who were enrolled in the EMPA-Kidney trial?

  • A. Patients with CKD and T2DM
  • B. Patients with a broad range of CKD with and without T2DM
  • C. Patients with macro-albuminuria (uACR >300 mg/g)
  • D. Patients with low eGFR (<45 mL/min/1.73m2)
Show the correct answer


Show transcript

Educational information

This lecture by Will Herrington was part of the EBAC-accredited symposium "Sharing international experience in CKD& SGLT2i: How to identify the right patient at the right moment?" held during the WCN 2023 in Bangkok, Thailand.


Will Herrington is a clinician scientist at the University of Oxford and a practicing Honorary Consultant Nephrologist at Oxford Kidney Unit. He is associate professor and jointly leads the Renal Studies Group as a Clinical Research Fellow.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant received from Boehringer Ingelheim and Lilly Alliance.

Watch other videos in this series Listen to the podcast

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: